Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1.31 AUD 1.55% Market Closed
Market Cap: 313.2m AUD
Have any thoughts about
Orthocell Ltd?
Write Note

Operating Margin
Orthocell Ltd

-151.3%
Current
-453%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-151.3%
=
Operating Profit
-10.2m
/
Revenue
6.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Orthocell Ltd
ASX:OCC
313.2m AUD
-151%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
28%
US
Amgen Inc
NASDAQ:AMGN
140.7B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country AU
Market Cap 313.2m AUD
Operating Margin
-151%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 311.8B USD
Operating Margin
28%
Country US
Market Cap 140.7B USD
Operating Margin
19%
Country US
Market Cap 115.7B USD
Operating Margin
38%
Country US
Market Cap 102.7B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Orthocell Ltd
Glance View

Market Cap
313.2m AUD
Industry
Biotechnology

Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.

OCC Intrinsic Value
1.89 AUD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-151.3%
=
Operating Profit
-10.2m
/
Revenue
6.8m
What is the Operating Margin of Orthocell Ltd?

Based on Orthocell Ltd's most recent financial statements, the company has Operating Margin of -151.3%.